Navigation Links
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
Date:11/8/2007

g Study FMS-031 also met the composite syndrome responder criteria

at three months (33% and 33% for the milnacipran 100 mg and 200 mg

groups, respectively) compared to patients treated with placebo (17%).

Statistically significant differences were also observed at the six-

month visit: 33% and 32% of patients met responder criteria for the

milnacipran 100 mg and 200 mg groups, respectively, compared to 19% of

patients in the placebo group.

Composite responder rates for fibromyalgia pain (pain and PGIC)

-- A statistically significant number of patients treated with milnacipran

during Study MLN-MD-02 met the composite pain responder criteria (39%

and 46% in the milnacipran 100 mg and 200 mg groups, respectively)

compared to patients treated with placebo (25%).

-- A statistically significant number of patients treated with milnacipran

during Study FMS-031 also met the composite pain responder criteria at

three months (45% and 45% in the milnacipran 100 mg and 200 mg groups,

respectively) compared to patients treated with placebo (27%).

Statistically significant differences were also observed at the six-

month visit: 44% and 45% of patients met the composite pain responder

criteria in the milnacipran 100 mg and 200 mg groups, respectively,

compared to 28% of patients in placebo group.

Tolerability

Milnacipran was generally well-tolerated, with the majority of adverse events (AEs) reported being mild to moderate in nature.

-- The most common treatment emergent AEs during the placebo-controlled

clinical trials included nausea (37% vs. 20% placebo), headache (18%

vs. 14% placebo), constipation (16% vs. 4% placebo), hot flushes (12%

vs. 2% placebo), hyperhidrosis (9% vs. 2 % placebo), vomiting (7% vs.

2%), palpitations (7% vs. 2%), heart rate increase (6% vs. 1
'/>"/>

SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... , Sept. 30, 2014  Proteomics is a ... a new report from Kalorama Information.  The healthcare market ... occurred in proteomics in the past two years.  ... agreements between private proteomic companies and academic institutions, ... novel proteomics innovator companies.  Kalorama observed the industry ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Biostructures, LLC Earns AATB Accreditation 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
(Date:9/30/2014)... Maryland-led research team has been awarded a three-year ... Health (NIH) to develop new imaging technologies and ... of how large networks of neurons in the ... will help researchers identify the precise interactions between ... decision-making and speaking, and alterations in these interactions ...
(Date:9/30/2014)... Charlotte, N.C. (PRWEB) September 30, 2014 ... as an option to help diabetics curb their sweet ... journal Nature this September, suggests that zero-calorie ... for type 2 diabetes. , The Weizmann Institute ... when they fed artificial sweeteners to mice, the mice ...
(Date:9/30/2014)... FL (PRWEB) September 30, 2014 Regenerative ... to two new clinics in Nashville, Tennessee. RMS welcomes ... Apnea Institute, and the expansion of a new treatment ... introduction of the Sleep Apnea Institute to Nashville, the ... suffer from sleep apnea: both diagnosed and undiagnosed. With ...
(Date:9/30/2014)... -- Medicare should cover low-dose computed tomography lung cancer ... a coalition of more than 60 patient and medical ... Cancer Alliance, the Society of Thoracic Surgeons, the American ... American Society of Clinical Oncology, made its point in ... Medicare & Medicaid Services (CMS). Such screening reduces ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacyā€¯ (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... ... tidbits people are learning about their ancestors is not just trivia. This information is highly ... understanding their familial and ancestral past. , ... Doylestown, PA (PRWEB) March 13, 2010 -- Noted author Donna Evans Strauss ...
... (Nasdaq: SIAL ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small ... ... , , ... ...
... 19 year olds and to those currently not in employment in a bid to increase awareness of safety at work. , ... , , ... ... ...
... 15, 2010 The Autism Consortium, an innovative research, ... enhancing clinical care for families with autism spectrum disorders ... study of genetic testing methods for autism spectrum disorders ... early online release in their eFirst pages today and ...
... AllegroMedical.com, ... meaning that just under 13 years, it has served more than a million customers nationwide. ... (Vocus) March 14, 2010 ... website launched in 1997. The first company to sell medical supplies online, it has grown ...
... its kind to date using cardiac computed tomography angiography, ... coronary artery disease are at higher risk of developing ... Henry Ford Hospital researchers say. Researchers analyzed the ... computed tomography angiography and found that those with a ...
Cached Medicine News:Health News:Author Proves What Celebrities are Learning in "Who Do You Think You Are?" is More Important Than They Realize 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 3Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 4Health News:Online Medical Supplies Superstore Ships 1 Millionth Order 2Health News:Family history is strong predictor of obstructive coronary artery disease using CCTA 2
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
... It's easy on delicate ... design and hydrophilic coating provide ... lubricating gel. It's easy to ... the catheter with its own ...
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Medicine Products: